Objective Response of Multiple Myeloma to Cyclosporin A

Two patients with advanced multiple myeloma were treated with oral low-dose cyclosporin A, one without other therapy and one in conjunction with chemotherapy to which the patient had been previously unresponsive. Both patients had objective laboratory and clinical responses. In the patient treated with cyclosporin A alone, decreasing serum IL-6 and beta-2-microglobulin levels fell as the clinical response evolved. Cyclosporin A deserves further evaluation in the therapy of multiple myeloma.